Torrent Pharmaceuticals has received approval from its Securities Transfer and Stakeholders Relationship Committee (STSRC) for the issuance of non-convertible debentures worth up to ₹12,500.00 crores. The committee meeting held on Monday approved the comprehensive debt fundraising initiative through private placement, marking a significant step in the pharmaceutical company's capital structure optimization strategy.

Committee Approval and Market Performance

The STSRC meeting approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures aggregating up to ₹12,500.00 crores in one or more tranches. The approval was disclosed to both BSE and NSE pursuant to Regulation 30 and Regulation 51 of SEBI Listing Regulations. Following the announcement, shares of the company ended 0.25% down at ₹3,875.10 apiece on the BSE.

Comprehensive Debenture Structure

The approved NCDs carry detailed specifications designed to attract institutional and retail investors:

Security Framework and Strategic Context

The debentures will be backed by a robust security framework to provide investor protection. The company will create a first ranking exclusive charge over designated accounts where NCD proceeds will be deposited and specified trademarks of the issuer. This security structure is designed to provide a minimum security cover of 1.10x, enhancing the investment appeal for potential subscribers.

This fundraising initiative comes after Torrent Pharma announced its acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a ₹19,500.00 crore deal. The private placement route allows the pharmaceutical company to access institutional capital efficiently while maintaining flexibility in terms and conditions.

Investment Features and Timeline

The listing on NSE's Wholesale Debt Market Segment will provide liquidity to investors, enabling secondary market trading of these instruments. The annual payment schedule for both coupon and principal offers predictable cash flows for investors. The specific tenure, allotment date, maturity date, and coupon rates will be determined and communicated at the time of issuance, providing the company with market timing flexibility.

The rights and privileges of NCD holders will be detailed in the final debenture trust deed to be executed between the company and the debenture trustee. This substantial debt fundraising positions the pharmaceutical company to pursue growth opportunities while optimizing its capital structure through non-dilutive financing.

Torrent Pharmaceuticals has completed the redemption of secured redeemable non-convertible debentures (NCDs) worth ₹142.84 crores on December 12, 2025. The pharmaceutical company informed both BSE and NSE about this corporate action through an official communication.

Debenture Redemption Details

The redemption covers a portion of the company's debt securities, with key parameters outlined below:

The redeemed amount represents 14.28% of the total non-convertible debentures issued by the company under the specified ISIN.

Regulatory Compliance

Torrent Pharmaceuticals has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both major stock exchanges where its shares are listed:

• BSE Limited (Scrip Code: 500420)
• National Stock Exchange of India (Scrip Code: TORNTPHARM)

The redemption and repayment were completed as scheduled. Company Secretary Chintan M. Trivedi signed the official communication to the exchanges.

Financial Impact

This redemption reduces the company's outstanding debt by ₹142.84 crores, leaving approximately ₹857.16 crores in NCDs still outstanding from the original ₹1,000 crores issue.